Antibe Therapeutics Inc. announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act was heard before...
Antibe Therapeutics Inc. announced that the Company sought an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act at a hearing before the...
Antibe Therapeutics Inc. today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration that otenaproxesul has been placed on clinical...
OTC Markets Group Announces the 2024 OTCQX Best 50
GlobeNewswire
January 18, 2024
NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), today announced the 2024 OTCQX® Best 50, a ranking of the top-performing OTCQX companies in the prior calendar year. The OTCQX Best 50 is an...
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain